$1.300
-0.039 (-2.99%)Zum Schluss
- High
- 1.335
- Open
- 1.300
- VWAP
- 1.30
- Vol
- 80.51K
- Mkt Cap
- —
- Low
- 1.270
- Amount
- 104.79K
- EV/EBITDA, TTM
- -2.34
MindWalk Holdings Corp., formerly ImmunoPrecise Antibodies Ltd., is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT technology and the LensAI platform, the Company unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. The platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed.
AI analysis of MindWalk Holdings Corp (HYFT)
buyMindWalk Holdings Corp (HYFT) is a good buy right now due to its recent inclusion in the Russell 3000 Index, which is expected to enhance visibility and attract institutional investors. The stock has shown a 52% year-over-year revenue growth in Q3, reaching $4.2 million, and a gross margin improvement to 60.63% in Q4 2026. However, the main risk is the negative earnings per share (EPS) of -0.08, indicating ongoing losses, but the potential for recovery is strong given the positive market sentiment and analyst support.
Bewertungskennzahlen
Event-Zeitleiste
News
8.508-19NewsfilterAI Drug Discovery Enters New Phase with Big Pharma Validation
- 8.508-10Newsfilter
MindWalk Holdings Demonstrates AI Drug Discovery Technology
8.507-24PRnewswireMindWalk Unveils AI Drug Discovery Platform at AMD Event
- 3.507-24Newsfilter
MindWalk Unveils AI Drug Discovery Platform at AMD Event
9.507-23PRnewswireMindWalk Holdings Reports 46% Revenue Growth in Fiscal 2026
HYFT FAQ — answered by Alphio AI
MindWalk Holdings Corp., formerly ImmunoPrecise Antibodies Ltd., is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT technology and the LensAI platform, the Company unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. The platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed. It operates in the Healthcare sector.
MindWalk Holdings Corp (HYFT) is a good buy right now due to its recent inclusion in the Russell 3000 Index, which is expected to enhance visibility and attract institutional investors. The stock has shown a 52% year-over-year revenue growth in Q3, reaching $4.2 million, and a gross margin improvement to 60.63% in Q4 2026. However, the main risk is the negative earnings per share (EPS) of -0.08, indicating ongoing losses, but the potential for recovery is strong given the positive market sentiment and analyst support.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.